RPL6 and gastric cancer: Follow up results demonstrated that patients with both RPL6 positive and cyclin E positive expressions showed a shorter survival time and poorer prognosis than the corresponding control and also indicated that patients with RPL6 negative expression showed longer survival time and better prognosis than patients with RPL6 positive expression, which suggested that RPL6 may served as a biomarker for gastric cancer prognosis and a gene target for gastric cancer therapy in clinic.